Metuchen Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for METUCHEN PHARMS, and what generic alternatives to METUCHEN PHARMS drugs are available?
METUCHEN PHARMS has one approved drug.
There is one US patent protecting METUCHEN PHARMS drugs.
There are thirty-nine patent family members on METUCHEN PHARMS drugs in twenty-five countries and eleven supplementary protection certificates in eleven countries.
Drugs and US Patents for Metuchen Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | AB | RX | Yes | No | 6,656,935 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |
Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | AB | RX | Yes | Yes | 6,656,935 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |
Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Metuchen Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | 7,501,409 | ⤷ Sign Up |
Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | 7,501,409 | ⤷ Sign Up |
Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | 7,501,409 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for METUCHEN PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-04-27 |
International Patents for Metuchen Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2283315 | ⤷ Sign Up |
Russian Federation | 2233273 | ⤷ Sign Up |
Bulgaria | 106566 | ⤷ Sign Up |
China | 1440393 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Metuchen Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1219609 | 122013000096 | Germany | ⤷ Sign Up | PRODUCT NAME: AVANAFIL UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/841 20130621 |
1219609 | C300618 | Netherlands | ⤷ Sign Up | PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621 |
1219609 | C01219609/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: SWISSMEDIC 65275 22.01.2016 |
1219609 | 1390047-7 | Sweden | ⤷ Sign Up | PRODUCT NAME: AVANAFIL; REG. NO/DATE: EU/1/13/841 20130621 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.